SCHEMBL6800972

SCHEMBL6800972

Cc1nc(Cl)sc1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.54
NPC1 O15118 6/20 0.54
RAB9A P51151 6/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
LMNA P02545 4/20 0.54
MAPT P10636 3/20 0.54
GAA P10253 2/20 0.54
TP53 P04637 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
ALOX5 P09917 2/20 0.47
KDM4E B2RXH2 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
HPGD P15428 2/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
COMT P21964 2/20 0.45
CASP3 P42574 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9955904 0.82 KMT2A (0.49) NPC1RAB9AKMT2AMAPTGAA
SCHEMBL9954402 0.82 KMT2A (0.47) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL2397216 0.81 JAK2 (0.42) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL92933 0.79 ALOX5 (0.66) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL9955315 0.79 TRPM8 (0.44) MEN1KMT2ALMNAMAPTGAA
SCHEMBL11753179 0.78 ALDH1A1 (0.60) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL2093272 0.78 ALDH1A1 (0.63) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL11471702 0.77 SMN1; SMN2 (0.56) ALDH1A1NPC1RAB9ALMNAMAPT
SCHEMBL11756042 0.77 MAPT (0.56) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL11751696 0.77 MAPT (0.56) ALDH1A1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686475-B2 THIAZOLIDINEDIONE DERIVATIVES HAVING HYPOGLYCAEMIC AND HYPOLIPIDAEMIC ACTIVITIES BEECHAM GROUP P.L.C. (GB) 2004-02-03 US disclosed
US-20030149054-A1 Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal BEECHAM GROUP P.L.C. 2003-08-07 US disclosed
US-20020049240-A1 NOVEL COMPOUNDS BEECHAM GROUP P.1.C. 2002-04-25 US disclosed
US-6288095-B1 ADMINISTERING 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE TO MAMMALS AS AN ANTIDIABETIC BEECHAM GROUP P.L.C. (GB) 2001-09-11 US disclosed
EP-0306228-B1 Substituted thiazolidinedione derivatives BEECHAM GROUP PLC (GB) 1999-11-17 EP disclosed
US-5756525-A USING A THIAZOLIDINEDIONE COMPOUND BEECHAM GROUP PLC (GB) 1998-05-26 US disclosed
EP-0842925-A1 Substituted thiazolidinedione derivatives BEECHAM GROUP PLC (GB) 1998-05-20 EP disclosed
US-5646169-A ADMINISTERING SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES TO HUMANS OR OTHER MAMMALS BEECHAM GROUP P.L.C. (GB) 1997-07-08 US disclosed
US-5521201-A SUBSTITUTED-THIAZOLIDINEDIONE DERIVATIVES BEECHAM GROUP P.L.C. 1996-05-28 US disclosed
US-5260445-A Hypoglycemic BEECHAM GROUP P.L.C. (GB) 1993-11-09 US disclosed
US-5232925-A Treating hypertension BEECHAM GROUP P.L.C. (GB) 1993-08-03 US disclosed
US-5194443-A Thiazolinediones, Hypoglycemic Agents, Antilipemic Agents BEECHAM GROUP P.L.C. (GB) 1993-03-16 US disclosed
US-5002953-A Substituted Thiazolidinedione Derivatives BEECHAM GROUP P.L.C. (GB) 1991-03-26 US disclosed
EP-0306228-A1 Substituted thiazolidinedione derivatives BEECHAM GROUP PLC (GB) 1989-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149054-A1 Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal TYK2, FABP3, FABP4 ALDH1A1 1150/4885NPC1 803/4885RAB9A 3737/4885
US-20020049240-A1 NOVEL COMPOUNDS GRK1, GRK3, GRK7 ALDH1A1 1255/4885NPC1 1168/4885RAB9A 2043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.